<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164267</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG 34</org_study_id>
    <secondary_id>2009-011725-14</secondary_id>
    <nct_id>NCT01164267</nct_id>
  </id_info>
  <brief_title>Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)</brief_title>
  <official_title>A Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus (RAD001) in Marginal Zone B-cell Lymphomas (MZL) EudraCT Number 2009-011725-14</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter open-label uncontrolled phase II study. There are no previous clinical&#xD;
      data to estimate the expected response rate of everolimus in MALT lymphomas and in the other&#xD;
      less common MZLs (i.e. nodal and splenic) refractory or relapsing after at least 1 prior&#xD;
      systemic treatment (chemotherapy or immunotherapy).&#xD;
&#xD;
      The primary objective of this study is to define the antitumor activity, in term of overall&#xD;
      response rate (ORR), as sum of complete remissions (CR) and partial remissions (PR) of&#xD;
      everolimus in relapsed or refractory marginal zone B-cell lymphomas.&#xD;
&#xD;
      The secondary objectives of this study are to assess safety, as acute or long-term toxicity,&#xD;
      response duration (RD) (time to relapse or progression) in responders and progression-free&#xD;
      survival (PFS) (time to disease progression or death from any cause) in all patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Body CT-Scan</measure>
    <time_frame>Every 12 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Marginal Zone B-cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven diagnosis of marginal zone B-cell lymphoma relapsing/refractory&#xD;
             following at least 1 prior systemic treatment (chemotherapy and or monoclonal&#xD;
             antibodies).&#xD;
&#xD;
          2. Any stage (Ann Arbor I-IV).&#xD;
&#xD;
          3. No evidence of histologic transformation to aggressive lymphoma.&#xD;
&#xD;
          4. Measurable or evaluable disease.&#xD;
&#xD;
          5. Age &gt; 18 years.&#xD;
&#xD;
          6. Life expectancy of at least 3 months.&#xD;
&#xD;
          7. ECOG performance status 0-1.&#xD;
&#xD;
          8. No prior diagnosis of neoplasm within 5 years, except cervical type 1 intraepithelial&#xD;
             neoplasia or localized non-melanomatous skin cancer.&#xD;
&#xD;
          9. In case of prior diagnosis of solid organ tumors, no treatment over the last 5 years&#xD;
             ond no current evidence of disease.&#xD;
&#xD;
         10. No prior chemo-or radiotherapy in the last 6 weeks, no prior immunotherapy in the last&#xD;
             8 weeks, no corticosteroids during the last 4 weeks unless low-dose prednisone&#xD;
             chronically administered for indications other than lymphoma or lymphoma-related&#xD;
             symptoms.&#xD;
&#xD;
         11. No major impairment of bone marrow function, renal function or liver function unless&#xD;
             due to lymphoma.&#xD;
&#xD;
         12. No evidence of active opportunistic infections, no HIV infection, no evidence of HBV&#xD;
             infection, no active HCV infection.&#xD;
&#xD;
         13. Women of childbearing potential are using effective contraception, are not breast&#xD;
             feeding, are not pregnant and agree not to become pregnant during participation in the&#xD;
             trial and during the 12 months thereafter. A negative pregnancy test is mandatory for&#xD;
             all patients &lt; 50 years (unless considered unnecessary by the investigator).&#xD;
&#xD;
             Men agree not to father a child during participation in the trial and during the 12&#xD;
             months thereafter.&#xD;
&#xD;
         14. No serious cardiac, neurological or psychiatric disorders potentially hampering&#xD;
             compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
         15. Fasting serum cholesterol ≤ 200 mg/dL or ≤ 5 mmol/L AND fasting triglycerides ≤ 200&#xD;
             mg/dL. NOTE: In case one or both of these thresholds are exceeded, the patient can&#xD;
             only be included after initiation of appropriate lipid lowering medication.&#xD;
&#xD;
         16. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with newly diagnosed MZL.&#xD;
&#xD;
          2. Patients with concomitant or past hematological malignancies.&#xD;
&#xD;
          3. Presence or history of CNS lymphoma localization (either parenchymal or meningeal&#xD;
             disease).&#xD;
&#xD;
          4. Cardiovascular disease (congestive heart failure; NYHA III or IV), unstable angina&#xD;
             pectoris, significant cardiac arrhythmias requiring chronic treatment, or prior&#xD;
             history of myocardial infarction in the last 3 months.&#xD;
&#xD;
          5. Serious underlying medical condition which could impair the ability of the patient to&#xD;
             participate in the trial (e.g. uncontrolled diabetes mellitus, gastric ulcers, active&#xD;
             autoimmune disease, ongoing infection e.g. HIV, hepatitis).&#xD;
&#xD;
          6. Concurrent anticancer drugs / treatments and experimental drugs. Previous radiation is&#xD;
             allowed, unless the indicator lesion(s) are in the irradiated field.&#xD;
&#xD;
          7. Previous organ transplantation&#xD;
&#xD;
          8. Participation in another clinical trial within 30 days prior to trial entry&#xD;
&#xD;
          9. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuele Zucca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IOSI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annarita Conconi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AOU Maggiore della Carità Novara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital AKH</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IEO</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INT</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU S. Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IOSI</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ielsg.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

